知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1821 条记录 (耗时 0.052 秒)

    Medical material and method for manufacturing same
    91.
    发明授权
    Medical material and method for manufacturing same 有权
    医疗材料及其制造方法

    公开(公告)号：US09192624B2

    公开(公告)日：2015-11-24

    申请号：US13911776

    申请日：2013-06-06

    申请人： Ajinomoto Co., Inc.

    发明人： Manabu Kitazawa ,  Satoru Ohashi ,  Yoko Masuzawa ,  Kousaku Ohkawa ,  Yasuhiko Tabata

    IPC分类号： A61K31/785 ,  D01F6/68 ,  A61L27/18 ,  A61L27/34 ,  A61L31/06 ,  A61L31/10 ,  A61L27/00 ,  D01D5/00

    CPC分类号： A61K31/785 ,  A61L27/00 ,  A61L27/18 ,  A61L27/34 ,  A61L31/06 ,  A61L31/10 ,  D01D5/0038 ,  D01F6/68 ,  C08L77/00

    摘要： The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.

    摘要翻译： 本发明的目的在于提供对活体安全的医疗用材料，具有高的生物相容性，对促进细胞分化是有用的。 本发明生产含有聚氨基酸作为主要成分的促进细胞分化的医药材料，其中聚氨基酸含有选自丙氨酸残基，缬氨酸残基，亮氨酸中的至少一种氨基酸残基 残基，异亮氨酸残基，苯丙氨酸残基，甘氨酸残基，谷氨酰胺残基，任选含有侧链保护基的天冬氨酸残基，任选地含有侧链保护基的酪氨酸残基，任选含有 侧链中的保护基，任选地含有侧链保护基的赖氨酸残基，以及任选地在侧链中含有保护基的谷氨酸残基。

    Polysorbitol-based osmotically active transporter and gene therapy using same
    93.
    发明授权
    Polysorbitol-based osmotically active transporter and gene therapy using same 有权
    基于聚山梨糖醇的渗透活性转运蛋白和使用其的基因治疗

    公开(公告)号：US09138488B2

    公开(公告)日：2015-09-22

    申请号：US14007064

    申请日：2011-08-12

    申请人： Myung Haing Cho ,  Chong Su Cho

    发明人： Myung Haing Cho ,  Chong Su Cho

    IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K31/047 ,  C12N15/87 ,  C08G63/685 ,  C08G63/91

    CPC分类号： A61K48/0041 ,  A61K9/0004 ,  A61K31/047 ,  A61K31/785 ,  C08G63/685 ,  C08G63/91 ,  C12N15/87 ,  Y10T428/2982

    摘要： The present invention relates to a biodegradable polysorbitol-based osmotically active transporter (PSOAT) and gene therapy using the same as a gene carrier. The biodegradable polysorbitol-based osmotically active transporter (PSOAT) of the present invention includes a sorbitol skeleton, which imparts an osmotic pressure to the cell membrane to improve membrane permeability, thereby exhibiting remarkably improved transfection efficiency. Further, the polysorbitol-based osmotically active transporter of the present invention exhibits high DNA binding ability, effectively protects DNA from nuclease, exhibits physicochemical properties suitable for use as a gene carrier, and has very low cytotoxicity in vitro and in vivo, thereby capable of being used as a gene carrier for gene therapy.

    摘要翻译： 本发明涉及可生物降解的聚山梨糖醇基渗透活性转运蛋白（PSOAT）和使用其作为基因载体的基因治疗。 本发明的可生物降解性聚山梨糖醇类渗透活性转运体（PSOAT）包括赋予细胞膜渗透压以改善膜通透性的山梨糖醇骨架，从而显着提高转染效率。 此外，本发明的基于聚山梨醇醇的渗透性活性转运体显示出高的DNA结合能力，有效地保护DNA免受核酸酶的影响，表现出适合用作基因载体的物理化学性质，并且在体外和体内具有非常低的细胞毒性， 被用作基因治疗的基因载体。

    LOW FREQUENCY GLATIRAMER ACETATE THERAPY
    94.
    发明申请
    LOW FREQUENCY GLATIRAMER ACETATE THERAPY 有权

    公开(公告)号：US20150250845A1

    公开(公告)日：2015-09-10

    申请号：US14720556

    申请日：2015-05-22

    申请人： Yeda Research & Development Co., Ltd.

    发明人： Ety Klinger

    IPC分类号： A61K38/02 ,  A61K9/00

    CPC分类号： A61K9/0019 ,  A61K31/19 ,  A61K31/785 ,  A61K38/02 ,  A61K38/07 ,  A61K38/16

    摘要： A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

    METHODS OF USING SMALL COMPOUNDS TO ENHANCE MYELOID DERIVED SUPPRESSOR CELL FUNCTION FOR TREATING AUTOIMMUNE DISEASES
    95.
    发明申请
    METHODS OF USING SMALL COMPOUNDS TO ENHANCE MYELOID DERIVED SUPPRESSOR CELL FUNCTION FOR TREATING AUTOIMMUNE DISEASES 审中-公开
    使用小化合物增强麻醉剂衍生抑制因子细胞功能治疗自身免疫性疾病的方法

    公开(公告)号：US20150224141A1

    公开(公告)日：2015-08-13

    申请号：US14591185

    申请日：2015-01-07

    申请人： Icahn School of Medicine at Mount Sinai

    发明人： Shu-Hsia Chen

    IPC分类号： A61K35/15 ,  A61K31/416 ,  A61K31/785

    CPC分类号： A61K35/15 ,  A61K31/416 ,  A61K31/785 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (MAP) kinase inhibitors. In other aspects, these methods include the administration of exogenous MDSCs or the use of endogenous MDSCs mobilized using stem cell mobilizers. In yet other aspects, compositions containing MDSCs and small compounds of the invention are provided.

    摘要翻译： 公开了使用小化合物增强骨髓来源的抑制细胞（MDSC）用于治疗自身免疫性疾病的抑制功能的方法。 在某些方面，小化合物是醋酸格拉司他和丝裂原活化蛋白（MAP）激酶抑制剂。 在其他方面，这些方法包括施用外源性MDSC或使用使用干细胞移动器调动的内源性MDSC。 在其它方面，提供了含有本发明的MDSC和小化合物的组合物。